Blocking LRRK2 activity is not a simple answer to Parkinson's disease
Mutations in the LRRK2 gene are the most common cause of genetic Parkinson's disease (PD). New research published in BioMed Central's open access journal Molecular Neurodegeneration demonstrates that loss of function of LRRK2 (by deletion of the kinase domain) leads to changes in motor co-ordination and causes anxiety-like behaviors and kidney degeneration in mice without affecting dopamine-mediated brain activity.
The protein LRRK2 is involved in regulating the structure and function of neurons. Aberrant LRRK2 has been shown experimentally to have subtle effects on dopamine signaling which may mirror the earliest changes in PD patients. In order to investigate how LRRK2 works researchers from Mayo Clinic deleted the kinase domain of LRRK2 protein in mice.
Dr Heather Melrose, who lead this study explained, "Since the gene is too big to delete the entire gene we targeted the kinase domain because we regarded this as the most important functional region. The specific section we deleted, exon 41, encodes the activation hinge of the kinase. The experimental strategy actually resulted, as we hoped, in a complete loss of the LRRK2 protein in the mice."
The team found that loss of LRRK2 did not affect dopamine signaling in the mice. The mice appeared to be normal however they had subtle behavioral changes similar to those previously seen for mice with the LRRK2 mutation G2019S, and sometimes seen in PD patients, such as increased anxiety. Deletion of the LRRK2 protein also affected kidney function.
Dr Melrose continued, "The most common mutation of LRRK2 (G2019S) is within the kinase domain however it is not thought to lead to a loss in kinase activity. Instead it is thought that the mutated LRRK2 kinase is somehow 'toxic' and anti-LRRK2 therapies are currently being designed to lower LRRK2 levels or block its kinase activity. Our results suggest that blocking normal LRRK2 activity causes emotional behavior changes in mice. These changes may be similar to anxiety disorder in PD, a disabling non-motor symptom of the disease which often precedes the motor defects by decades. Our data adds evidence to a different theory, that some biological consequences of the LRRK2 mutations may be a loss rather than gain of function."
It seems then that LRRK2 is a complicated protein and that restoring normal activity to patients with PD is not going to be simple. Not only may anti-LRRK2 therapies have side effects on the kidney but they also may disrupt some brain functions and sensory processing. These are going to be important considerations for design and use of LRRK2-based therapeutics.
More information: LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors
Kelly M Hinkle, Mei Yue, Bahareh Behrouz, Justus C Dachsel, Sarah J Lincoln, Erin E Bowles, Joel E Beevers, Brittany N Dugger, Caroline B Kent, Beate Winner, Iryna Prots, Kenya Nishioka, Wenlang Lin, Dennis W Dickson, Christopher G Janus, Matthew J Farrer and Heather L Melrose
Molecular Neurodegeneration (in press)
Provided by BioMed Central
- Parkinson's mutation stunts neurons Nov 22, 2006 | not rated yet | 0
- Synergistic interaction enhances pathogenesis of Parkinson's disease Dec 23, 2009 | not rated yet | 0
- New 'mouse models' give insight to gene mutation that is potential cause of Parkinson's disease Mar 31, 2010 | not rated yet | 0
- Study finds promising clue to mechanism behind gene mutation that causes Parkinson's disease Mar 25, 2011 | not rated yet | 0
- Enzyme fights mutated protein in inherited Parkinson's disease Jun 26, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
The Durability of Bone: Long Falls
4 hours ago I am doing a paper on the physics in Valve's Portal and got interested in the "Long Fall Boots" that prevent any damage no matter how far you fall. I...
Is energy convertible to matter?
6 hours ago Can we convert energy to matter?
Rotating electron as a dipole is this right?
8 hours ago An electron as shown by the Stern Gerlach experiment behaves like a dipole (albeit only in one of two states). I have been trying to figure out how...
Dipole term in multipole expansion
12 hours ago Hi. I'm having some difficult in understanding something about the dipole term in a multipole expansion. Griffiths writes the expansion as a sum of...
Bubbles in a Pre-Boiling/Boiling pot of water
14 hours ago How is it that bubbles form on the bottom of a surface of a pot of boiling water? I think that there is probably an elementary answer to this...
Assumptions of Griffith's fracture theory
May 21, 2013 Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
- More from Physics Forums - Classical Physics
More news stories
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...
Parkinson's & Movement disorders May 20, 2013 | not rated yet | 0
Faulty energy production in brain cells leads to disorders ranging from Parkinson's to intellectual disability
Neuroscientist Patrik Verstreken of VIB (Flanders Institute for Biotechnology) and KU Leuven has shown for the first time that dysfunctional mitochondria in brain cells can lead to learning disabilities. The link between ...
Parkinson's & Movement disorders May 17, 2013 | 4 / 5 (2) | 0
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson's disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The ...
Parkinson's & Movement disorders May 09, 2013 | 5 / 5 (1) | 0 |
New research reveals that Solanaceae—a flowering plant family with some species producing foods that are edible sources of nicotine—may provide a protective effect against Parkinson's disease. The study appearing today ...
Parkinson's & Movement disorders May 09, 2013 | not rated yet | 0
(Medical Xpress)—Researchers at the Stanford University School of Medicine have exposed the possible function, in the healthy brain, of a mysterious molecule that has been strongly implicated in Parkinson's ...
Parkinson's & Movement disorders May 01, 2013 | 5 / 5 (3) | 0 |
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
15 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
13 hours ago | 4.9 / 5 (11) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
15 hours ago | 4.6 / 5 (7) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
8 hours ago | 3.7 / 5 (3) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
9 hours ago | 5 / 5 (4) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
10 hours ago | 5 / 5 (1) | 0 |